Needham & Company LLC reaffirmed their buy rating on shares of Moderna (NASDAQ:MRNA) in a report published on Monday, AnalystRatings.com reports. The firm currently has a $28.00 price target on the stock.
Other analysts also recently issued research reports about the company. Piper Jaffray Companies upped their price target on Moderna from $24.00 to $30.00 and gave the stock an overweight rating in a research note on Wednesday, May 8th. Zacks Investment Research upgraded Moderna from a hold rating to a buy rating and set a $15.00 price target on the stock in a research note on Saturday, August 10th. JPMorgan Chase & Co. restated a buy rating and issued a $24.00 price target on shares of Moderna in a research note on Sunday, August 11th. Chardan Capital restated a buy rating and issued a $40.00 price target on shares of Moderna in a research note on Sunday, June 2nd. Finally, Oppenheimer upped their price target on Moderna from $27.00 to $31.00 and gave the stock an outperform rating in a research note on Wednesday, May 29th. Ten analysts have rated the stock with a buy rating, The company has an average rating of Buy and a consensus target price of $26.30.
Moderna stock opened at $12.67 on Monday. The stock has a market cap of $4.25 billion and a P/E ratio of -2.56. The stock has a 50 day moving average of $13.85. Moderna has a twelve month low of $11.54 and a twelve month high of $29.79.
Moderna, Inc, a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.